A randomized phase III trial of trastuzumab + ALpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with PIK3CA mutated previously treated HER2+ Advanced BrEasT cancer.

    Trial Coordinator
    Dorene Polizzi

    Monitor
    Mariana Pardo Contreras, Magdalena Sánchez, Carmen Comune, Giuseppe Achille, Daniela Celotto

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Targeted Accrual
    300

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login